Last edition
News about "Biopharmaceutical Innovation"
Argo Biopharma Doses First Patient in Phase 1 siRNA Trial
Argo Biopharma has dosed the first participant in the phase I trial of BW-41012, its Factor XI-targeting siRNA therapy for preventing thromboembolic diseases.
Biopharmaceutical Innovation | 22/07/2026 | By News Bureau | 137
India Poised to Become a Global Biopharma Leader: Anupriya Patel
Union Minister Anupriya Patel said India is well-positioned to become a global biopharma leader, highlighting the Biopharma SHAKTI initiative’s goal of launching 100 biologics by 2047. She urged the industry to strengthen capabilities in biologics and biosimilars.
Biopharmaceutical Innovation | 12/06/2026 | By News Bureau | 137
Travere Therapeutics Receives USPTO Patent Allowance for Filspari Use in IgA Nephropathy
Travere Therapeutics has secured a Notice of Allowance from the USPTO for a patent application covering specific methods of using Filspari (sparsentan) in the treatment of IgA nephropathy, strengthening its rare kidney disease portfolio.
Biopharmaceutical Innovation | 29/05/2026 | By News Bureau | 203
Pharming Secures EU Approval for Joenja as First Targeted Treatment for Rare Immune Disorder APDS
Pharming Group has received European Commission approval for Joenja, expanding treatment access for patients with activated PI3K delta syndrome and strengthening therapeutic options for rare immune disorders.
Biopharmaceutical Innovation | 26/05/2026 | By News Bureau | 104
Incyte and Genesis Molecular AI have expanded their strategic collaboration to deploy advanced molecular AI technologies and proprietary research data, aiming to accelerate drug discovery and develop next-generation therapies through AI-powered molecular design.
Biopharmaceutical Innovation | 22/05/2026 | By News Bureau | 286
Alebund Pharmaceuticals has completed patient enrollment in its global phase 3 RESPOND-2 study evaluating AP301, a next-generation phosphate binder for CKD patients on dialysis.
Biopharmaceutical Innovation | 07/05/2026 | By News Bureau | 163
GSK's Efimosfermin Secures FDA Breakthrough and EMA PRIME Status for MASH Treatment
The dual regulatory designations from US FDA and European Medicines Agency fast-track development of GSK’s investigational liver therapy for metabolic dysfunction-associated steatohepatitis.
Biopharmaceutical Innovation | 29/04/2026 | By News Bureau | 196
ImmunoForge Unveils LMT15 Platform to Transform CNS Drug Delivery
The clinical-stage biotech firm ImmunoForge is advancing its next-generation blood-brain barrier shuttle technology, combining enhanced brain permeability with long-acting formulations to accelerate therapies for CNS and rare diseases.
Biopharmaceutical Innovation | 24/04/2026 | By News Bureau | 127
Abbisko's Irpagratinib Secures EMA Orphan Drug Tag for Liver Cancer
European regulator grants rare disease designation to FGFR4 inhibitor, boosting its clinical development and commercial prospects in hepatocellular carcinoma.
Biopharmaceutical Innovation | 01/04/2026 | By News Bureau | 153
EU Grants Conditional Approval to Rezurock for Chronic GVHD Treatment
European Commission authorises belumosudil for patients aged 12 plus with limited treatment options, marking a significant advance in managing a life-threatening post-transplant condition.
Biopharmaceutical Innovation | 01/04/2026 | By News Bureau | 117
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy